Imperia

Researchers are evaluating the effectiveness of Ravulizumab in improving the daily living activities of people recently diagnosed with generalized myasthenia gravis (MG) who test positive for anti-AChR antibodies. This study focuses on patients with early-stage MG and aims to measure how well Ravulizumab works in this specific group. The study is designed to assess changes in symptoms related to MG using the MG-ADL (Myasthenia Gravis-Activities of Daily Living) score over a period of 50 weeks. Participants will receive Ravulizumab treatment during the study. Those enrolled must have a confirmed diagnosis of MG with anti-AChR antibodies and meet specific clinical criteria such as disease duration of 3 years or less and MGFA class IIb to IV. Vaccination against Neisseria meningitidis is required before starting treatment, or participants must receive antibiotic prevention as per guidelines. The study excludes those who have had certain recent treatments or who have conditions that make Ravulizumab unsuitable. During the 50-week study period, participants will be monitored regularly to track changes in their MG-ADL total scores from the start to week 50. Researchers will also observe safety and adherence to treatment. Participants will complete questionnaires and follow scheduled visits to help assess the impact of Ravulizumab on their daily symptoms and overall health status.